TABLE 1.
Baseline characteristics of the study population (hypersensitivity pneumonitis patients receiving antifibrotics)
| Patients | 30 |
| Age years | 70.2±8.4 |
| Sex | |
| Male | 26 (86.7) |
| Female | 4 (13.3) |
| Smoking status | |
| Ex-smokers | 19 (63.3) |
| Never-smokers | 11 (36.7) |
| Antifibrotics | |
| Pirfenidone | 14 (46.7) |
| Nintedanib | 16 (53.3) |
| Identification of inciting antigen | 25# (83.3) |
| Surgical lung biopsy | 7 (23.3) |
| Comorbidities | |
| GORD | 12 (40) |
| Pulmonary hypertension | 9 (30) |
| Arterial hypertension | 13 (43.3) |
| Diabetes | 6 (20) |
| Coronary artery disease | 6 (20) |
| Supplementary oxygen | 11 (36.7) |
| FVC % pred | 74.2 ±18.3 |
| DLCO % pred | 46.9±16 |
Data are presented as n, mean±sd or n (%). GORD: gastro-oesophageal reflux disease; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide. #: avian n=21, house mould n=3, isocyanate n=1.